Discover recent clinical trial failures in depression and explore potential pathways for advancing antidepressant drug ...

Tesla and SpaceX CEO Elon Musk clarified that he uses only "a small amount once every other week or something like that" ...

In terms of the newest collaboration, the health care professionals said they decided that having all the services under one ...

Spravato is the first ketamine-based medicine approved to treat depression, and also the first of a new class of glutamate NMDA receptor-targeting drugs that have ended a decades-long drought at ...

Myers Squibb Company, Johnson & Johnson, Bausch Health Companies Inc, AbbVie Inc. Read 's Market Analysis on Investing.com ...

HOPE Therapeutics, wholly owned by NRx Pharmaceuticals (NRXP), announced signing of a binding Letter of Intent, LOI, to acquire a majority ...

Q4 2024 Earnings Call Transcript March 17, 2025 Operator: Good morning, ladies and gentlemen, and welcome to the NRx ...

most studies of ketamine in depression have relied on either intravenous or intranasal administration, the latter resulting in the approval of J&J’s Spravato (esketamine) for TRD in 2019 and for ...

Billions of dollars will be injected into Australia's public healthcare system under the 2025 Federal Budget delivered ...

Mar. 13, 2025 — New research shows that people with eating disorders are more harshly judged than those suffering from depression, making it much harder for them to seek ... Worldwide Study ...

Investing during a period of economic depression or recession can be daunting. However, choosing the right depression stocks can help you weather a period of uncertainty and protect your financial ...

Repetitive transcranial magnetic stimulation is used to treat various neuropsychiatric but its considerable power consumption and large size limit its potential for broader utility. Here, the ...